Ventrinova
Ventrinova Inc. is dedicated to advancing regenerative medicine through innovative therapies and research. The company focuses on developing safe and effective regenerative drugs and therapies worldwide, aiming to modify current medical practices by addressing the root causes of diseases and disorders. Their pioneering approach includes pharmacological reversal of cardiac damage, stimulation of endogenous growth of cardiac myocytes, and the use of cellular therapies and biomaterials for treating various diseases and injuries. They emphasize translational research to bring laboratory therapies to hospitals and battlefield applications, with the goal of helping patients avoid invasive surgeries and lengthy recoveries. Their work encompasses regenerative treatments for heart muscle, nerves, and musculoskeletal tissues, contributing to fundamental and translational research to understand the body's regenerative capacities.
Industries
Nr. of Employees
small (1-50)
Services
Collection and processing of patient-derived tissues (blood, bone marrow, adipose) into concentrated injectables (e.g., platelet-rich plasma, bone marrow aspirate concentrate) and local administration for musculoskeletal conditions.
Research programs that perform preclinical large-animal studies, evaluate pharmacologic modulation of cell-cycle pathways, and develop catheter-based vector delivery approaches to restore myocardial function after infarction.
Research and development services for designing cellular therapeutics and biomaterials intended for tissue repair and clinical translation.
Collection and processing of patient-derived tissues (blood, bone marrow, adipose) into concentrated injectables (e.g., platelet-rich plasma, bone marrow aspirate concentrate) and local administration for musculoskeletal conditions.
Research programs that perform preclinical large-animal studies, evaluate pharmacologic modulation of cell-cycle pathways, and develop catheter-based vector delivery approaches to restore myocardial function after infarction.
Research and development services for designing cellular therapeutics and biomaterials intended for tissue repair and clinical translation.
Expertise Areas
- Cardiac regenerative therapy development
- Autologous orthobiologic therapies
- Translational research and preclinical development
- Biomaterials for tissue repair
Key Technologies
- Cell therapy
- Gene therapy / viral vector delivery
- Catheter-based intracardiac delivery
- Autologous biologic concentrates (PRP, bone marrow aspirate concentrate, adipose-derived)
News & Updates
Preclinical Study Demonstrates Cardiac Muscle Regeneration
The company announced the publication of a preclinical study showing the ability to regenerate cardiac muscle in large animals after a heart attack.
Preclinical Study Demonstrates Cardiac Muscle Regeneration
The company announced the publication of a preclinical study showing the ability to regenerate cardiac muscle in large animals after a heart attack.